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Diagnostic Significance of Antibodies to the Epstein-Barr Virus-Specific Membrane Antigen gp250 
Methods for the demonstration of antibodies to the mem-
brane antigen of Epstein-Barr virus (EBV) and for EBV-
neutralizing antibodies have been described by different 
authors [1-3]. Because of the complexities of these assays 
and because they are difficult to perform and to read, how-
ever, they have not been widely used for routine diagnos-
tic purposes. Therefore, only limited data are available 
about antibodies to E B V membrane antigens or about neu-
tralizing antibodies in EBV-infected individuals. The pres-
ent study was undertaken in order to find out the frequency 
of antibodies to the E B V membrane antigen, the timing 
of their appearance, and their possible diagnostic sig-
nificance. We focused our interest on gp250 — this mem-
ber of the membrane-antigen complex mediates the bind-
ing of the virus to the target cell and induces neutralizing 
antibodies [4]. In addition, this protein (as well as the an-
tigenically closely related gp350 [4]) is a candidate for a 
possible E B V subunit vaccine [5]. Furthermore, it is ex-
pressed on induced EBV-producer cells and can be easily 
demonstrated after radioiodination of cell-surface proteins 
[6]. For the demonstration of antibodies against gp250, 
we used a radioimmunoprecipitation technique in combi-
nation with SDS-PAGE and autoradiography, a method 
that is very sensitive and is highly specific. 
Materials and Methods 
Radioiodination and solubilization of cell-surface pro-
teins. The EBV-producing, MA-positive cell line P3HR-1 
and the EBV-negative line B J A B were cultured as previ-
ously described [7]. For induction of EBV antigens, P3HR-
1 cultures were treated with 40 ^g of phorbol-12 myristate-
13 acetate/ml immediately after subculture. Cells were har-
vested for surface labeling three days later. 
Lactoperoxidase-catalyzed iodination of cell-surface 
protein was performed as described earlier [8]. Iodinated 
cells were suspended in PBS at a concentration of 2 x 
107 cells/ml and were mixed with an equal volume of 1% 
Nonidet P-40 (NP-40) in PBS supplemented with Trasylol 
(Bayer, Leverkusen, Federal Republic of Germany; final 
concentration, 200 kallikrein inhibitor units/ml) and 
phenylmethane sulfonyl fluoride (E. Merck, Darmstadt, 
F R G ; final concentration, 2 mmol). After incubation for 
30 min on ice, the cells were centrifuged at 2,000 g for 30 
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min and the supernatant was applied to a Sephadex G-25 
column. The first radioactive peak containing the labeled 
membrane protein was used for the subsequent steps. 
Immunoprecipitation. The labeled NP-40 extracts were 
first precleared with a rabbit antiserum to human periph-
eral blood lymphocytes (PBLs) in order to remove most 
of the lymphocyte-specific proteins and to also remove pro-
teins that bind nonspecifically to immobilized protein A . 
Protein A-Sepharose C L - 4 B (Pharmacia, Uppsala, 
Sweden) was incubated with an equal volume of antise-
rum to PBLs for 3 hr and was washed three times with 
0.5% NP-40 in PBS. We mixed 0.5 ml of the coated beads 
with 3.5 ml of NP-40 extract prepared from 8 x 106 of 
surface-labeled cells and gently rotated the mixture for 3 
hr at room temperature. The beads were removed and the 
supernatant was incubated again for 3 hr with 0.5 ml of 
beads coated with antiserum to PBLs as above. The 
precleared extract was diluted to 5 ml and was either im-
mediately used for immunoprecipitation or stored frozen 
at - 2 0 C. We then mixed 125 \A of this extract with 10 
\x\ of the serum to be tested and incubated the mixture over-
night in the cold. Immune complexes were isolated by add-
ing 100 \A of a 20% (vol/vol) Protein A-Sepharose sus-
pension in 0.5% NP-40 in PBS. The mixture was rotated 
for 3 hr at room temperature, then the beads were washed 
twice with 0.5% NP-40 in PBS, transferred to new tubes, 
washed another two times with PBS, and washed once 
more with distilled water. The washed beads were sus-
pended in electrophoresis-sample buffer (50 m M T r i s - H C l 
[pH 7.0], 2% SDS, 5% 2-mercaptoethanol, and 3% su-
crose) and heated to 100 C for 5 min; the supernatant was 
used for electrophoresis. 
SDS-PAGE. SDS-PAGE was performed exactly as de-
scribed by Bayliss and Wolf [7]. For autoradiography of 
the dried gel, a Kodak X-omat S film (Rochester, NY) was 
used in combination with an intensifying screen. 
EBV serology. Titers of IgG and IgM antibody to vi-
ral capsid antigen (VCA), IgG antibody to early antigen 
(EA), and antibody to Epstein-Barr nuclear antigen 
(EBNA) were determined by indirect immunofluorescence 
methods [9]. 
Patient's sera. The sera used in this study came from 
patients of different clinics and general practitioners, 
mainly in Munich, and were provided by Professor F. Dein-
hardt (Max von Pettenkofer Institute, Munich). 
Results 
Immunoprecipitation of gp250. Gp250 was im-
munoprecipitated from 1 2 5I-labeled membrane proteins of 
P3HR-1 cells by a serum pooled from patients with 
nasopharyngeal carcinoma who are known to have high 
titers of antibodies to membrane antigen. Control precipi-
tates with this serum from extracts of B J A B cells were nega-
tive as were precipitates from P3HR-1 extracts with seven 
different EBV-negative sera (figure 1, lanes A - C ) . As nearly 
all sera precipitated a number of cellular proteins, labeled 
P3HR-1 extracts were precleared by using a rabbit antise-
rum to human P B L s . This procedure reduced the back-
grund activity considerably; only a few faint, unspecific 
bands were seen in addition to the E B V protein gp250 and 
traces of E B V proteins gp350 and p80 (figure 1, lanes D 
and E). The sensitivity of the method was evaluated by 
immunoprecipitation of gp250 with serial dilutions of the 
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Figure 1. Immunoprecipitation of EBV-specific mem-
brane antigen gp250. Lane A: extract of surface-labeled 
EBV-producer cells (P3HR-1) immunoprecipitated with 
a serum that was positive for antibody to membrane 
antigen. Lane B: control precipitate from labeled E B V -
negative cells (BJAB) with serum that was positive for 
antibody to membrane antigen. Lane C: same as in A , 
but precipitated with serum that was negative for E B V . 
Lanes D and E: immunoprecipitations from precleared 
P3HR-1 extract with serum that was positive for antibody 
to membrane antigen (D) and that was negative for 
antibody to E B V (£) . 
above mentioned serum pool. Starting with 10 \x\ of un-
diluted serum, gp250 was still detectable at a dilution of 
K64. 
Determination of antibodies to gp250 in patient's sera. 
One hundred twenty-one sera from 84 individuals who were 
positive for E B V were tested for the presence of antibod-
ies to gp250. In addition, all sera were examined for IgG 
antibodies to V C A and to E B N A and most of them were 
also examined for IgM antibodies to V C A and to E A . 
Thirty sera were drawn from patients with infectious 
mononucleosis. Twenty-six showed the typical serological 
pattern of acute infection with EBV: they were positive 
for IgG antibody to V C A and IgM antibody to V C A and 
negative for antibody to E B N A . Antibodies to gp250 were 
lacking in 24 (92.3%) of these sera; in the remaining two 
(7.7%), only traces of antibodies to gp250 were found. 
Four patients with the clinical diagnosis of infectious 
mononucleosis showed serological signs of the convales-
cent phase. Two of the patients had sera that were nega-
tive for IgM antibody to V C A and had trace amounts of 
antibody to E B N A . Antibody to gp250 was negative in 
one serum sample and weakly positive in the other. The 
other two individuals were positive for IgG and IgM anti-
bodies to V C A , as well as positive for antibody to E B N A . 
One of these two lacked antibody to gp250 and only trace 
amounts were found in the other. 
Five individuals with acute infection with E B V were fol-
lowed up for a longer period of time. In two of them, an-
tibody to gp250 appeared four and five weeks after the 
onset of infectious mononucleosis, whereas two others were 
still negative for antibody 12 and 14 weeks later (antibod-
ies to E B N A were present at this time). A 14-year-old girl 
with clinical symptoms of persistent, active infection with 
E B V such as lymphadenitis colli, recurrent low grade fe-
ver, and headaches, did not develop antibody to gp250 
or antibody to E B N A during an observation period of 18 
months. 
In 40 persons, a past infection with E B V was diagnosed 
on the basis of the presence of antibody to V C A and anti-
body to E B N A . In addition, IgM antibody to V C A was 
tested for in 13 sera with negative results in all of them. 
Thirty-four (85%) of these individuals were clearly posi-
tive for antibody to gp250; one (2.5%) was weakly posi-
tive. Five (12.5%) persons lacked antibodies to gp250 but 
did show antibodies to V C A as well as to E B N A . Two of 
these persons had had serologically proven, acute infec-
tious mononucleosis 10 and 12 weeks before; the other 
three (a 62-year-old woman and a 27-year-old woman with 
her eight-month-old son) had no history of clinically ap-
parent infection with EBV. The 62-year-old woman was 
hospitalized because of indigestion, hepatomegaly, and 
leukopenia. No cause was found for these symptoms; a 
bone marrow aspirate showed reactive plasmocytosis. The 
27-year-old woman was apparently healthy. Her son, how-
ever, had congenital hepatomegaly and very slight mal-
Table 1. Antibodies to gp250 in sera from patients with acute, recent, and past infections with E B V . 
Anti-gp250 
Anti-VCA 
Clinical diagnosis No. positive, 
(no. of subjects) IgG IgM Anti-EBNA no. negative (% positive) 
Acute infection (26) + + - 2*, 24 (7.7*) 
Recent infection (6) + + / - - / + 2*, 4 (33.3*) 
Past infection (52) + - + 49, 3 (94.0) 
* Only traces of antibody to gp250 were found. 
formation of fingers and toes (rather plump thumbs and 
toes and incomplete syndactilia between the second and 
third toes). 
Fourteen persons with histologically and serologically 
proven EBV-related nasopharyngeal carcinoma were also 
tested for antibody to gp250; all were found strongly 
positive. 
A l l results are summarized in table 1. 
Discussion 
Eighty-four individuals with acute or past infection with 
E B V were examined for antibodies to the E B V membrane 
antigen gp250. Ninety-four percent of persons with past 
infection with E B V were found to be positive for antibod-
ies to gp250. In 92% of all acute cases, these antibodies 
were completely lacking, whereas in the remaining 8% only 
traces were seen. Antibody to gp250 did not appear be-
fore four to six weeks after the onset of disease. Our data 
suggest that antibody to gp250 is a useful marker for past 
infection with EBV; lack of this antibody in the presence 
of other markers of E B V indicates acute infection with 
EBV. The absence of antibody in two patients with signs 
of persistent, active infection with E B V and in a third case, 
an asymptomatic woman who gave birth to a child with 
hepatomegaly and slight malformations, could be a hint 
for a possible role of these antibodies in the prevention 
of endogenous reinfection and intrauterine infection. How-
ever, this has to be tested in a large number of similar cases. 
Using immunofluorescence techniques, Klein et al. [1] 
found that antibodies to the E B V membrane antigen were 
present only in sera that were positive for antibody to V C A , 
and that they appeared de novo in patients during the acute 
phase of infectious mononucleosis. 
Testing for EBV-neutralizing capacity is another ap-
proach to the detection of antibodies to membrane anti-
gen as there is strong evidence that neutralizing antibod-
ies are directed against membrane-antigen determinants 
[4]. Neutralizing antibodies could be detected in most hu-
man sera after infection. In one study [10], these antibod-
ies were found in nearly all early acute-phase sera, whereas 
in another study [11], neutralizing antibodies were undetec-
table by the fifth to seventh week after the onset of infec-
tious mononucleosis. These conflicting results probably 
were a consequence of the different methods used. Re-
cently, Sairenji et al. [12] showed that complement-
independent neutralizing antibodies were undetectable or 
only slightly positive in the sera of patients with acute in-
fectious mononucleosis, but that complement-dependent 
neutralizing antibodies were present in these cases. 
For the detection of antibody to gp250 in this study, 
immunoprecipitation of iodinated membrane proteins of 
P3HR-1 cells induced by 12-O-tetradecanoyl phorbol-13 
acetate (TPA) was used in combination with SDS-PAGE 
and autoradiography. This technique allowed us to dem-
onstrate antibodies to a single E B V protein in a large num-
ber of sera. The method has the advantage of high sensi-
tivity and specificity and needs only minimal amounts of 
serum. A n alternative approach for the demonstration of 
antibodies to a single membrane-antigen component (with 
use of an E L I S A ) was described recently by Luka et al. 
[13]. Such tests could be used for screening the large num-
ber of individuals necessary to study the function of anti-
body to membrane antigen and neutralizing antibodies in 
E B V infection. Highly sensitive tests are also an impor-
tant prerequisite for a possible E B V vaccination program. 
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Dose Response of Influenza A/Washington/897/80 (H3N2) Avian-Human 
Reassortant Virus in Adult Volunteers 
Reassortant viruses containing the H A and neuraminidase 
(NA) genes of a human influenza A virus and the other 
six R N A segments (i.e., "internal genes") of an avian in-
fluenza virus are being developed as possible live-virus vac-
cine strains for use in humans [1]. Several aspects of the 
natural history of influenza A virus and the polymorphism 
of its genes underlie this approach to the development of 
a stable, attenuated reassortant influenza A virus vaccine 
useful for humans. First, certain genes of avian influenza 
A viruses have been selected over a long period of time 
to function efficiently in cells of their natural host. The 
nucleotide sequence of these genes differs significantly 
from that of the corresponding genes of human influenza 
A viruses [2]. Hence, it is likely that some avian influenza 
viruses will replicate poorly in cells of primate respiratory 
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epithelium and thereby be attenuated. Second, one would 
also expect attenuated influenza A avian-human reassor-
tant viruses that contain such genetically divergent genes 
to retain their attenuation phenotype following a restricted 
infection in man. 
Ten avian influenza A viruses were initially evaluated 
as potential donor strains in squirrel monkeys, a primate 
that is susceptible to experimental infection with influenza 
A viruses [3]. This survey was conducted to identify avian 
influenza viruses that were restricted in their replication 
in the respiratory tract of a susceptible primate. Several 
avian influenza A viruses that grew poorly in the upper 
and lower respiratory tract of squirrel monkeys were iden-
tified. One of these avian influenza viruses, the A / M a l -
lard/6750/78 (H2N2) strain, was mated with three differ-
ent human influenza A viruses, and avian-human influenza 
A reassortant viruses that possessed the H A and N A genes 
of their human influenza A virus parent and the six inter-
nal genes of their avian influenza A virus parent [1, 4] were 
isolated. The avian-human influenza reassortant viruses 
were as restricted in the lower respiratory tract of mon-
keys as their avian influenza virus parent. The reassortants 
grew to a titer that was 1,000 times less than that of their 
human influenza A virus parent [1,4]. This indicated that 
the six internal genes of the A/Mallard/6750/78 virus 
reproducibly attenuated human influenza A viruses for 
primates. One of the avian-human influenza A virus reas-
sortants (human parent, A/Washington/80 [H3N2]) was 
